Based on BOT successfully completing a Phase 1b study of BTX 1503 during 1Q CY2018 with the results above, I reckon the chances of the The Phase 2 clinical trial being a success are extraordinarily high.
Up your BOT
Not advice, DYOR
LEAD PRODUCT: BTX 1503 (MODERATE TO SEVERE ACNE) - Phase 2 clinical trial
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
0.015(4.05%) |
Mkt cap ! $699.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.0¢ | $1.537M | 4.028M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 91664 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |